Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial
Regulatory enforcement around compounded GLP-1s has been a moving target, and new branded entrants tend to increase scrutiny, not decrease it
Risks include inaccurate dosing, contamination, and poor storage
2 Concurrently, the Food and Drug Administration (FDA) threatened to restrict access to the bulk ingredients required for compounding these medications, noting that GLP-1 drugs were no longer in a shortage
Ehrsam, S
(The third, Foundayo, just got FDA approval in April, so its too new for spending data.) In 2024, Medicare spent over $19.3 billion on Ozempic and Mounjaro, according to gross spending data from CMS